4 results
Primary Objective: - To study the effect of mucositis on the absorption of sublingually delivered fentanyl (Abstral®) in head and neck cancer patients treated with chemoradiotherapy. Secundary Objective:- To study the effect of xerostomia on the…
Primary objective:To show that concomitant use of telaprevir (1125 mg BID) does not lead to a relevant decrease (> 20%) in the paroxetine parameter AUC0-24h compared to paroxetine alone.Secondary objectives:To determine the ratio of the…
To determine and compare PK profiles of two of the most used ROOs in cancer patients: one intranasal fentanyl formulation (INFC, Instanyl®) and one sublingual fentanyl formulation (SLF, Abstral®).
The primary objective of this study is to demonstrate superiority in overall survival (OS) and comparable safety when eflornithineis added to lomustine compared to lomustine alone in patients with anaplastic astrocytoma (AA) that progress/recur…